Kohl probes device DTC, threatens ad ban push

Share this article:
Kohl probes device DTC, threatens ad ban push
Kohl probes device DTC, threatens ad ban push
Sen. Herb Kohl said he was “prepared to call for future moratoriums” on DTC for new medical devices, citing “real risks and serious complications.”

Kohl (D-WI), who chairs the Senate Special Committee on Aging, said “Physicians and consumers must be appropriately educated about these critical devices and their benefits and risks alike, What we do in the near term will be dependent on the proactive actions of FDA and industry.”

His comments followed committee hearings into DTC for medical devices in which physicians argued that device DTC undermines the doctor-patient relationship and can raise healthcare costs. Upbeat ads for the Cypher stent, from J&J's Cordis, came in for special criticism. Cordis' “Life wide open” TV campaign debuted last Thanksgiving but has since been restricted to a single market outside Baltimore.

The device industry's DTC spending remains small by comparison to that for pharmaceuticals – according to TNS Media Intelligence, device makers spent $193 million on advertising last year – but it's growing fast. In convening the hearings, Kohl said the device industry was “beginning to get into the game,” and that it was time the FDA began subjecting it to the same scrutiny as it does pharmaceutical manufacturers.
Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...